secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001104659-25-055709
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma reports 80% ORR, 50% CR for rigosertib in RDEB-SCC Phase 2 study
-----------------------------------------------------------------------------

- Rigosertib Phase 2 ISS in RDEB-SCC showed 80% overall response rate (ORR) with 50% complete responses (CR) in evaluable patients.
- Results published on June 3, 2025; study enrolled patients who failed prior immune checkpoint inhibitor therapy.
- Company also posted corporate presentations for rigosertib and narazaciclib; narazaciclib trials are on hold pending funding.
- Traws seeking partnership opportunities for rigosertib in RDEB-SCC, a high unmet need with no approved treatments.
- Clinical safety database for rigosertib includes >1,300 patients across prior cancer studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925055709/0001104659-25-055709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925055709/tm2516986d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-055709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer